This was demonstrated by using a syngeneic model of prostate cancer with CRISPR/Cas9-mediated deletion of Rab27a and PD-L1 to reduce EV release and block PD-L1 protein expression, respectively. This evidence concerns the gene RAB27A and prostate cancer.